Receptos, a biotech with a Phase 3 drug candidate for relapsing multiple sclerosis, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2008 and has yet to generate any revenue from drug sales, plans to list on the NASDAQ under the symbol RCPT. Receptos initially filed confidentially on February 13, 2013. Credit Suisse, Leerink Swann and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
